SpringerLink
Log in

PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma

  • Image of the Month
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, et al. Updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol. 2019;76:151–6. https://doi.org/10.1016/j.eururo.2019.05.022.

    Article  PubMed  Google Scholar 

  2. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–90.

    Article  CAS  Google Scholar 

  3. Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA–PET in prostate cancer management. Nat Rev Urol. 2016;13:226.

    Article  CAS  Google Scholar 

  4. Baccala A, Sercia L, Li J, Heston W, Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007;70:385–90.

    Article  Google Scholar 

  5. Raveenthiran S, Esler R, Yaxley J, Kyle S. The use of 68Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04432-2.

Download references

Author information

Author notes

  1. L. M. Mittlmeier, M. Unterrainer, H. Ilhan and M. Staehler contributed equally to this work.

Authors and Affiliations

  1. Department of Urology, University Hospital, LMU Munich, Munich, Germany

    L. M. Mittlmeier, S. Rodler, C. G. Stief & M. Staehler

  2. Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany

    L. M. Mittlmeier, M. Unterrainer, A. Todica, P. Bartenstein & H. Ilhan

  3. Department of Radiology, University Hospital, LMU Munich, Munich, Germany

    M. Unterrainer & C. C. Cyran

Authors
  1. L. M. Mittlmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Unterrainer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Todica
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. C. Cyran
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Rodler
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Bartenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. G. Stief
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Ilhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Staehler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Staehler.

Ethics declarations

Conflict of interest

Michael Staehler: Consultant: Pfizer, GlaxoSmithKline, Novartis, Bayer, Roche, Aveo, EUSAPharm, Astellas, Ipsen, Exelixis, Pelloton, EISAI, BMS, MSD; honoraria: Pfizer, GlaxoSmithKline, AVEO, Novartis, Bayer, EUSAPharm, Astellas, Ipsen, Exelixis, Pelloton, EISAI, BMS, MSD; research funding: Pfizer, GlaxoSmithKline, AVEO, BMS, Novartis, Bayer, Roche/Genentech, Immatics, Wilex, Ipsen, Exelixis, EISAI. All other authors declare that they have no relationships or interests that could have direct or potential influence or impart bias on the work.

Informed consent

The radiopharmaceutical was used on an individual patient basis according to German Pharmaceuticals Act §13(2b). Informed written consent was obtained from the patient. The ethical committee of LMU Munich waives additional approval for case reports from clinical practice.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Image of the month

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mittlmeier, L.M., Unterrainer, M., Todica, A. et al. PSMA PET/CT for tyrosine-kinase inhibitor monitoring in metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging 47, 2216–2217 (2020). https://doi.org/10.1007/s00259-019-04636-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-019-04636-6

Search

Navigation